Skip to main content

Table 1 Drugs, doses and therapeutic regimens applied in the presented studies

From: 1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis

Experimental model Drug Route of administration Dose Treatment regimen
Experimental metastasis (Fig. 1) 1-MNA Per os in drinking water 100 mg/kg/day Treatment initiated 7 days prior cancer transplantation and continued to the end of the experiment
1,4-DMP
Spontaneous metastasis (single drug treatment) (Fig. 2) 1-MNA Per os in drinking water 100 mg/kg/day Continuously from the 7th day of the experiment to the end of the experiment
1,4-DMP
Matrigel plugs (Fig. 3) 1-MNA Per os in drinking water 100 mg/kg/day Continuously starting from the day of matrigel plugs transplantation
1,4-DMP
Cyclophosphamide intraperitoneally 25 mg/kg/day On days 0, 3, 5
Spontaneous metastasis (combined treatment) (Fig. 4 and 5) 1-MNA Per os in drinking water 100 mg/kg/day Continuously from the 1st day of the experiment to the end of the experiment
1,4-DMP
Cyclophosphamide Intraperitoneally 25 mg/kg/day From the 7th day of the experiment, 3 times each week